ClinicalTrials.gg
TerminatedNCT04768881Updated Aug 23, 2024Results posted

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

A Phase 2 interventional study of Selinexor and Pembrolizumab in Locally Advanced Unresectable or Metastatic Melanoma, sponsored by Karyopharm Therapeutics Inc. Terminated at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
The trial was terminated due to a lack of sufficient anti-melanoma tumor signal for the combination of selinexor + pembrolizumab.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing pembrolizumab in Melanoma — 20 open to participants now, 41 under way, 7 of them phase 3. pembrolizumab · Melanoma.

Enrollment
74th of 87
15 · median 53
Started
2021
with 8 others
Phase 2
49 of 87
12 open now
Registered
59th of 87
by date

Among the 87 studies testing pembrolizumab in Melanoma, this one is the 74th largest by enrollment, is one of 9 that started in 2021, is one of 49 in phase 2, and was the 59th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

20 of the 87 studies testing pembrolizumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing pembrolizumab in Melanoma, or all of them as a file.
02

Study summary

Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm A and Acquired resistance to initial CPI therapy in Arm B. Participants who have disease progression (PD) after discontinuation of CPIs, especially in neoadjuvant or adjuvant therapy, will be considered to have acquired resistance in this study. Participants will receive study treatment (Selinexor and Pembrolizumab) until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.

03

Conditions studied

  • Locally Advanced Unresectable or Metastatic Melanoma

Browse trials for

Keywords

  • Karyopharm
  • Locally advanced unresectable or metastatic melanoma
  • KPT-330
  • Recurrent advanced melanoma
  • Selinexor
  • Pembrolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to (≥) 18 years at the time of .
  • Participant must have a confirmed diagnosis of locally advanced unresectable stage III or stage IV melanoma not amenable to local therapy.

    1. Participants must have confirmed PD per (RECIST) on or within 12 weeks of the last dose of /L1 monotherapy or combination therapy (including relatlimab or other anti-LAG-3 mAb) per Society for Immunotherapy in Cancer Guidelines (Kluger,2020).
    2. Arm A (primary resistance): participant has disease progression after receiving at least 6 weeks of prior anti-PD-1/L1 mAb with the best response as PD, or stable disease (SD) less than (\<) 6 month (participants with a partial response [PR] or complete response [CR] who have disease progression within 6 months will be considered to have primary resistance in this study).
    3. Arm B (secondary/acquired resistance): participant has disease progression after receiving at least 6 months of prior anti-PD-1/L1 mAb with the best response as CR, PR, or SD greater than (>) 6 months (participants who have disease progression after or adjuvant therapy, will be considered to have secondary resistance in this study).
    4. Participants who progress on or within 12 weeks after elective discontinuation of anti-PD-1/L1 mono or combination treatment in the absence of PD or treatment limiting toxicity must have confirmed PD per RECIST.
  • Participants should have at least 1 prior line of CPI therapy but no more than 2.
  • according to RECIST v1.1.
  • Participants with stable previously treated are permitted in this study.
  • (ECOG) performance status less than or equal to (≤) 1.
  • Adequate bone marrow function at screening, defined as:

    1. (ANC) ≥1.5 * 10\^9 per liter (L).
    2. ≥10 gram per deciliter (gm/dL) (≥6.2 millimoles per liter [mmol/L]).
    3. count ≥100 * 10\^9/L.
  • Serum direct ≤1.5 * (ULN); (AST) and alanine transaminase (ALT) ≤2.5 * ULN (with confirmed liver metastases: AST and ALT ≤5 * ULN).
  • Calculated (CrCl) ≥15 milliliters per minute (mL/min) based on the Cockcroft and Gault formula.
  • Female participants of must have a negative serum pregnancy test at screening and agree to use highly effective methods of throughout the study and for at least four months following the last dose of study treatment. Childbearing potential excludes: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy.
  • Male participants who are sexually active must use highly effective methods of contraception throughout the study and for at least four months following the last dose of study treatment. Male participants must agree not to donate sperm during the study treatment period.
  • Written informed consent signed in accordance with federal, local, and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • uveal or ocular melanoma.
  • Active central nervous system (CNS) metastases or other CNS (e.g., meningeal) involvement.
  • Participants must have resolution or improvement of immune-mediated treatment related adverse reactions related to prior treatment(s) to Grade ≤1 without maintenance therapy or his or her previous baseline prior to the corresponding CPI therapy

    a. History of immune-mediated treatment related adverse reactions leading to discontinuation of prior anti-programmed death protein 1 (), anti-programmed death protein ligand 1 (PD-L1), or anti programmed death protein ligand 2 (PD-L2) monoclonal antibodies (mAbs) or severe reaction to any mAb or any which in the opinion of the Investigator precludes future use of anti-PD-1/PDL1 therapy.

  • Concurrent systemic steroid therapy higher than physiologic dose (>10 milligrams per day [mg/day] of prednisone or equivalent).
  • Previous treatment with selinexor or other exportin 1 (XPO1) inhibitors.
  • Insufficient time since or not recovered from procedures or anti-cancer therapy, defined as:

    1. Not recovered from major surgery ≤28 days prior to Day 1 dosing. Minor procedures, such as , dental work, or placement of a port or intravenous (IV) line for infusion are permitted.
    2. Have ongoing anti-cancer therapy-related toxicities (CTCAE) Grade >1. In specific cases, participants whose toxicity has stabilized or with Grade 2 non-hematologic toxicities can be allowed following documented approval by the Sponsor's Medical Monitor
    3. Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing
    4. Palliative radiotherapy >14 days prior to the study is allowed
    5. Received drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug (whichever is shorter), prior to Cycle 1 Day 1 (C1D1).
  • (e.g., nasal spray influenza vaccine) ≤14 days prior to the intended C1D1.
  • Impairment of gastrointestinal (GI) function or GI disease that could significantly alter the absorption of selinexor (e.g., vomiting, or diarrhea that is CTCAE version 5.0 grade >1).
  • less than (\<) 4 months based on the opinion of the Investigator
  • Active pneumonitis requiring steroid therapy.
  • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral).
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, prevent the participant from giving , or being compliant with the study procedures.
  • Female participants who are pregnant or lactating.
  • Active virus treated with antiviral therapy for hepatitis B within 8 weeks with a viral load >100 international units per milliliter (IU/mL).
  • Untreated virus positive without documentation of negative viral load per institutional standard.
  • positive with CD4+T-cells ≤350 cells per microliter, positive viral load per institutional standard, and a history of acquired immunodeficiency syndrome defining opportunist infections in the last year.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Arm A: Primary resistance to Initial CPI Therapy

    Participants will receive a dose of 80 milligrams (mg) selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg intravenously (IV) once in every six weeks (Q6W), both on Day 1 of a 6-week cycle until progressive disease (PD), intolerable toxicity or withdrawal from the study, whichever occurs first.

    Drug: Selinexor · Drug: Pembrolizumab

  • Experimental
    Arm B: Acquired Resistance to Initial CPI Therapy

    Participants will receive a dose of 80 mg selinexor orally once weekly (QW) and a dose of pembrolizumab 400 mg IV Q6W, both on Day 1 of a 6-week cycle until PD, intolerable toxicity or withdrawal from the study, whichever occurs first.

    Drug: Selinexor · Drug: Pembrolizumab

Interventions

  • Dose and formulation: 80 mg (4 tablets of 20 mg)

    Also known as: KPT-330, XPOVIO®

  • Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Assessed as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR). ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to less than (\<)10 millimeter (mm). PR was defined as at least a 30 percentage (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 24 months)

Secondary outcomes

  1. Progression-free Survival (PFS) as Per RECIST v 1.1

    PFS was defined as time from date of first treatment to the date of first confirmed progressive disease (PD), assessed by RECIST 1.1 is objectively documented or death due to any cause. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From the date of randomization until disease progression or death, due to any cause (up to 24 months)

  2. Overall Survival (OS)

    OS was defined as the time from date of first study treatment until death due to any cause. If death event did not occur during the follow-up period, the participant was censored at the date of discontinuation from the study (i.e. withdrawal of consent), or date of last participating visit (e.g., a telephone contact with participant status being alive) on or before database cutoff date, whichever occurs first.

    Time frame: From the date of first study treatment up to death (up to 24 months)

  3. Complete Response Rate (CRR)

    Complete response rate was defined as percentage of participants who had achieved a complete response (CR) per RECIST 1.1. As per RECIST version 1.1, CR was defined as disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduced in the short axis to \<10 mm.

    Time frame: Up to 101 weeks

  4. Duration of Response (DOR) as Per RECIST v 1.1

    DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From first occurrence of CR or PR until disease progression or death, whichever occurs first (up to 24 months)

  5. Percentage of Participants With Disease Control Rate (DCR) as Per RECIST v 1.1

    Disease control rate was defined as percentage of participants who have a response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study. Percentage values were rounded off.

    Time frame: Up to 24 months

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: From start of the study treatment up to 24 months

  7. Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Parameters

    Clinical laboratory parameters included clinical chemistry, hematology and urinalysis. Number of participants with clinically significant laboratory abnormalities which were deemed clinically significant by the investigator were reported.

    Time frame: From start of the study treatment up to 24 months

  8. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs included body temperature, blood pressure (systolic blood pressure and diastolic blood pressure). Measurements were made after the participant had been resting supine for a minimum of 5 minutes. The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in vital signs values were reported.

    Time frame: From start of the study treatment up to 24 months

  9. Number of Participants With Clinically Significant Changes in Physical Examination

    Number of participants with clinically significant physical examination abnormalities including general appearance, dermatological, head, eyes, ears, nose, throat, respiratory, cardiovascular, abdominal, lymph nodes, musculoskeletal, and neurological examinations. Number of participants with clinically significant physical examination abnormalities which were deemed clinically significant by the investigator were reported.

    Time frame: From start of the study treatment up to 24 months

  10. Number of Participants With Severity of Adverse Events Assessed Using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    AEs are graded using the following criteria using Common Terminology Criteria for Adverse events v5.0: Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL; Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to AE.

    Time frame: From start of the study treatment up to 24 months

07

Results

Posted Aug 23, 2024
Limitations and caveats
This study was stopped prematurely due to a lack of sufficient anti-tumor signal for the selinexor/pembrolizumab combination treatment in participants with advanced or metastatic melanoma.

Participant flow

This study was conducted at 13 sites in United States of America from 12 May 2021 to 22 September 2023.

Participant flow — Overall Study
MilestoneArm A: Primary Resistance to Initial Checkpoint Inhibitor (CPI) TherapyArm B: Acquired Resistance to Initial CPI Therapy
Started96
Completed00
Not completed96
Withdrew: Completed study follow-up02
Withdrew: Death32
Withdrew: Study terminated by sponsor22
Withdrew: Withdrawal by subject20
Withdrew: Other20

Outcome measures

PrimaryOverall Response Rate (ORR) Assessed as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR). ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to less than (\<)10 millimeter (mm). PR was defined as at least a 30 percentage (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 24 months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Assessed as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Percentage of participantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Overall Response Rate (ORR) Assessed as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.133.3 (7.5 to 70.1)16.7 (0.4 to 64.1)
SecondaryProgression-free Survival (PFS) as Per RECIST v 1.1

PFS was defined as time from date of first treatment to the date of first confirmed progressive disease (PD), assessed by RECIST 1.1 is objectively documented or death due to any cause. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From the date of randomization until disease progression or death, due to any cause (up to 24 months)
Reported as:
Median · Months
Progression-free Survival (PFS) as Per RECIST v 1.1
MonthsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Progression-free Survival (PFS) as Per RECIST v 1.13.75 (2.14 to NA)6.24 (2.10 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from date of first study treatment until death due to any cause. If death event did not occur during the follow-up period, the participant was censored at the date of discontinuation from the study (i.e. withdrawal of consent), or date of last participating visit (e.g., a telephone contact with participant status being alive) on or before database cutoff date, whichever occurs first.

Time frame:
From the date of first study treatment up to death (up to 24 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Overall Survival (OS)NA (8.31 to NA)NA (13.08 to NA)
SecondaryComplete Response Rate (CRR)

Complete response rate was defined as percentage of participants who had achieved a complete response (CR) per RECIST 1.1. As per RECIST version 1.1, CR was defined as disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduced in the short axis to \<10 mm.

Time frame:
Up to 101 weeks
Reported as:
Number · Percentage of participants
Complete Response Rate (CRR)
Percentage of participantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Complete Response Rate (CRR)22.2 (2.8 to 60.0)16.7 (0.4 to 64.1)
SecondaryDuration of Response (DOR) as Per RECIST v 1.1

DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions, any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From first occurrence of CR or PR until disease progression or death, whichever occurs first (up to 24 months)
Reported as:
Median · Months
Duration of Response (DOR) as Per RECIST v 1.1
MonthsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Duration of Response (DOR) as Per RECIST v 1.1NA (1.61 to NA)NA (NA to NA)
SecondaryPercentage of Participants With Disease Control Rate (DCR) as Per RECIST v 1.1

Disease control rate was defined as percentage of participants who have a response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) with reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study. Percentage values were rounded off.

Time frame:
Up to 24 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control Rate (DCR) as Per RECIST v 1.1
Percentage of participantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Percentage of Participants With Disease Control Rate (DCR) as Per RECIST v 1.144.4 (13.7 to 78.8)50.0 (11.8 to 88.2)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
From start of the study treatment up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Participants with TEAEs96
Participants with Serious TEAEs32
SecondaryNumber of Participants With Clinically Significant Abnormalities in Clinical Laboratory Parameters

Clinical laboratory parameters included clinical chemistry, hematology and urinalysis. Number of participants with clinically significant laboratory abnormalities which were deemed clinically significant by the investigator were reported.

Time frame:
From start of the study treatment up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Parameters
ParticipantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Clinical Chemistry00
Hematology00
Urinalysis00
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Vital signs included body temperature, blood pressure (systolic blood pressure and diastolic blood pressure). Measurements were made after the participant had been resting supine for a minimum of 5 minutes. The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in vital signs values were reported.

Time frame:
From start of the study treatment up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Systolic Blood Pressure00
Diastolic Blood Pressure00
Body Temperature00
SecondaryNumber of Participants With Clinically Significant Changes in Physical Examination

Number of participants with clinically significant physical examination abnormalities including general appearance, dermatological, head, eyes, ears, nose, throat, respiratory, cardiovascular, abdominal, lymph nodes, musculoskeletal, and neurological examinations. Number of participants with clinically significant physical examination abnormalities which were deemed clinically significant by the investigator were reported.

Time frame:
From start of the study treatment up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Physical Examination
ParticipantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Number of Participants With Clinically Significant Changes in Physical Examination00
SecondaryNumber of Participants With Severity of Adverse Events Assessed Using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

AEs are graded using the following criteria using Common Terminology Criteria for Adverse events v5.0: Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL; Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to AE.

Time frame:
From start of the study treatment up to 24 months
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events Assessed Using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
ParticipantsArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Grade 100
Grade 252
Grade 344
Grade 400
Grade 500

Adverse events

Collected over From start of the study treatment up to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Primary Resistance to Initial CPI Therapy3/9 (33.3%)3/9 (33.3%)9/9 (100%)
Arm B: Acquired Resistance to Initial CPI Therapy2/6 (33.3%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
Splenic vein thrombosisBlood and lymphatic system disorders0/91/6
PneumoniaInfections and infestations1/91/6
Acute kidney injuryRenal and urinary disorders0/91/6
Deep vein thrombosisVascular disorders0/91/6
Adrenal insufficiencyEndocrine disorders1/90/6
Lower gastrointestinal haemorrhageGastrointestinal disorders1/90/6
SepsisInfections and infestations1/90/6
FallInjury, poisoning and procedural complications1/90/6
Subdural haematomaInjury, poisoning and procedural complications1/90/6
Wound complicationInjury, poisoning and procedural complications1/90/6
Most frequent other events
Showing 10 of 86
Most frequent other events
EventArm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI Therapy
NauseaGastrointestinal disorders6/96/6
Decreased appetiteMetabolism and nutrition disorders6/91/6
FatigueGeneral disorders5/91/6
ConstipationGastrointestinal disorders4/93/6
VomitingGastrointestinal disorders4/93/6
DysgeusiaNervous system disorders0/93/6
ThrombocytopeniaBlood and lymphatic system disorders4/92/6
AnaemiaBlood and lymphatic system disorders4/91/6
Vision blurredEye disorders0/92/6
DiarrhoeaGastrointestinal disorders3/92/6

Baseline characteristics

Modified intent-to-treat (mITT) population consisted of all participants who received at least one dose of any study treatment.

Age, Continuous
Age, Continuous(Years)Arm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI TherapyTotal
Mean61.4 ± 13.9553.7 ± 12.4058.3 ± 13.48
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI TherapyTotal
Female336
Male639
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI TherapyTotal
Hispanic or Latino213
Not Hispanic or Latino6511
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Primary Resistance to Initial CPI TherapyArm B: Acquired Resistance to Initial CPI TherapyTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White6511
More than one race000
Unknown or Not Reported213
08

Study locations

13 sites
  • UCLA
    Los Angeles, California 90095, United States
  • TOI Clinical Research
    Pasadena, California 91105, United States
  • BRCR Global
    Plantation, Florida 33322, United States
  • Minnesota Oncology Hematology
    Minneapolis, Minnesota 55404, United States
  • Great Plains Health
    North Platte, Nebraska 69101, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • New York Oncology Hematology
    Albany, New York 12206, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • OH Care Clinical Trials
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44144, United States
  • Texas Oncology-Austin Central
    Austin, Texas 78731, United States
  • Texas Oncology - Baylor Sammons Center
    Dallas, Texas 75246, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Sep 2023, 28 months.

Results were first posted in Aug 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Feb 24, 2021
StartActual
May 12, 2021
Primary completionActual
Sep 22, 2023
CompletionActual
Sep 22, 2023
Results first posted
Aug 23, 2024
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04768881
Responsible party
Sponsor
First posted
Feb 24, 2021
Start date
May 12, 2021
Primary completion
Sep 22, 2023
Completion
Sep 22, 2023
Results posted
Aug 23, 2024
Last update
Aug 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selinexor · Pembrolizumab

Start the discussion